Literature DB >> 9525545

Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.

P G Steg1, T Laperche, J L Golmard, J M Juliard, H Benamer, D Himbert, P Aubry.   

Abstract

OBJECTIVES: We sought to examine the relation between time to treatment and 90-min patency rates in patients receiving intravenous streptokinase (SK) or accelerated tissue-type plasminogen activator (t-PA).
BACKGROUND: Early patency of the infarct-related artery is a major determinant of survival after thrombolysis for acute myocardial infarction. Some data suggest that time to treatment may influence the efficacy of nonfibrin-specific thrombolytic agents in restoring early patency of the infarct-related vessel.
METHODS: We performed a retrospective analysis of a cohort of 481 patients receiving thrombolytic therapy for acute myocardial infarction <6 h after pain onset, all of whom underwent 90-min coronary angiography. Patency of the infarct-related artery was graded by two observers who had no knowledge of the treatment received or the time between pain and therapy.
RESULTS: There was no difference in baseline clinical or angiographic characteristics according to the timing or nature of treatment. Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 or 3 patency rate after SK correlated negatively with the time between onset of pain and thrombolysis (r = 0.8, p = 0.05), whereas the 90-min patency rate after t-PA appeared stable as a function of time to treatment. When patients were categorized as having received treatment <3 or > or = 3 h after pain onset, the patency rate was similar with t-PA, but significantly higher when SK was administered early rather than late, regardless of whether TIMI flow grades 2 and 3 were pooled (86.9% vs. 59.4%, p = 0.0001) or TIMI flow grade 3 alone was considered to indicate patency (81.7% vs. 53.6%, p = 0.0001). Multivariate logistic regression analysis showed a negative effect of time to treatment on the patency probability for SK (p = 0.0001) but not for t-PA.
CONCLUSIONS: The efficacy of streptokinase but not t-PA in restoring early coronary patency after intravenous thrombolysis is markedly lower when patients are treated later after onset of pain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525545     DOI: 10.1016/s0735-1097(98)00018-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  Time from symptom onset to treatment of patients with acute ST-elevation myocardial infarction.

Authors:  F Zijlstra
Journal:  Neth Heart J       Date:  2002-11       Impact factor: 2.380

2.  [Prognostic significance of ST segment change in acute myocardial infarct].

Authors:  K Wegscheider; K L Neuhaus; R Dissmann; U Tebbe; U Zeymer; R Schröder
Journal:  Herz       Date:  1999-08       Impact factor: 1.443

3.  A study of coronary artery patency in relation to the index event in patients with myocardial infarction thrombolysed with streptokinase.

Authors:  R K Gokhroo; Sajal Gupta; Devendra Singh Bisht; Deepak Padmanabhan
Journal:  Heart Asia       Date:  2014-04-26

4.  In-hospital time to treatment of patients with acute ST elevation myocardial infarction treated with primary angioplasty: determinants and outcome. Results from the registry of percutaneous coronary interventions in acute myocardial infarction of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte.

Authors:  R Zahn; A Vogt; U Zeymer; A K Gitt; K Seidl; M Gottwik; M A Weber; W Niederer; B Mödl; H-J Engel; U Tebbe; J Senges
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

Review 5.  Prehospital fibrinolysis versus primary percutaneous coronary intervention in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Vincent Roule; Pierre Ardouin; Katrien Blanchart; Adrien Lemaitre; Julien Wain-Hobson; Damien Legallois; Joachim Alexandre; Rémi Sabatier; Paul Milliez; Farzin Beygui
Journal:  Crit Care       Date:  2016-11-05       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.